Abbott Laboratories (NYSE: ABT) has outperformed the S&P 500 in 2023, with a stock price increase of 18% compared to the S&P 500’s 6%. This growth is attributed to strong quarterly results and optimistic projections.
Financially, Abbott’s price-to-sales (P/S) ratio stands at 5.6 against the S&P 500’s 3.1, while its price-to-free cash flow (P/FCF) ratio is 37.3 compared to 20.9 for the index. The company’s revenues increased to $42 billion over the past 12 months, while net income was reported at $13 billion, yielding a net income margin of 31.9%.
As of July 7, 2025, Abbott’s debt is $15 billion with a market capitalization of $233 billion, leading to a strong debt-to-equity ratio of 6.3%. However, investors should be cautious due to potential macroeconomic risks, including tariffs and declining COVID-19 testing demand, which could impact future growth.
